Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | PTGES | O14684 | 1/20 | 0.63 |
| ▸ | CES2 | O00748 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303949 | 1.00 | TOP2A (0.72) | TOP2APTPN1USP2LMNAHIF1A | |
| SCHEMBL13293124 | 0.95 | TOP2A (0.65) | TOP2APTPN1USP2LMNAHIF1A | |
| SCHEMBL13301903 | 0.94 | TOP2A (0.64) | TOP2APTPN1USP2LMNAHIF1A | |
| SCHEMBL13301930 | 0.94 | TOP2A (0.64) | TOP2APTPN1USP2LMNAHIF1A | |
| SCHEMBL13293272 | 0.92 | USP2 (0.61) | TOP2APTPN1USP2LMNAHIF1A | |
| SCHEMBL13293267 | 0.91 | USP2 (0.60) | TOP2APTPN1USP2LMNAHIF1A | |
| SCHEMBL14374339 | 0.91 | PTPN1 (0.80) | TOP2APTPN1USP2LMNAHIF1A | |
| SCHEMBL5459389 | 0.91 | PTPN1 (0.80) | TOP2APTPN1USP2LMNAHIF1A | |
| Ilekudinol C SCHEMBL16704973 | 0.90 | PTPN1 (0.85) | TOP2APTPN1USP2LMNAHIF1A | |
| Ilekudinol C SCHEMBL3506041 | 0.90 | PTPN1 (0.85) | TOP2APTPN1USP2LMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010068668-A1 | 23-SUBSTITUTED DERIVATIVES OF LUPANE-TYPE PENTACYCLIC TRITERPENOIDS | ADVANCED LIFE SCIENCES, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144688-A1 | 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids | ADVANCED LIFE SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144688-A1 | 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids | ADVANCED LIFE SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144688-A1 | 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids | BRCA1, PGF, LSS | TOP2A 949/4885PTPN1 3524/4885USP2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.